Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains an Outperform rating on Denali Therapeutics (NASDAQ:DNLI) but lowers the price target from $37 to $31.
August 09, 2023 | 7:48 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Denali Therapeutics' price target has been lowered from $37 to $31 by Wedbush, though the Outperform rating is maintained.
The lowering of the price target by Wedbush could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained Outperform rating indicates that the analyst still sees potential upside, which could counterbalance the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100